24/7 Market News Snapshot 28 May, 2025 – bioAffinity Technologies, Inc. Common Stock (NASDAQ:BIAF)

May 28, 2025

DENVER, Colo., 28 May, 2025 (www.247marketnews.com) – (NASDAQ:BIAF) are discussed in this article.
BioAffinity Technologies, Inc. (BIAF) has experienced a noteworthy surge in its stock price, opening at $0.28 and rising to $0.310, marking an impressive increase of approximately 13.80%. This uptick follows a previous close of $0.272, indicating strong upward momentum and heightened investor interest, as reflected in a trading volume of 5.27 million shares. Analysts are observing this price action closely, as it may signify a breakout from a key resistance level, potentially altering market dynamics for the company. Vigilance is required around the previous close, while further upward movement could lead to reaching recent highs.

In addition to its promising stock performance, BioAffinity Technologies has made significant strides in cancer research with the announcement of a newly issued patent from the U.S. Patent and Trademark Office. The patent, titled “Compositions and Methods for Treating Cancer” (Patent No. 12,305,171), outlines an innovative methodology targeting the CD320 and LRP2 receptors on cancer cell membranes. This cutting-edge treatment approach aims to selectively eliminate cancer cells linked to various malignancies such as lung, breast, prostate, brain, and skin cancers. Current research is underway to develop a topical treatment specifically for skin-related cancers, potentially expanding the implications of this discovery.

Central to this innovation is the application of small interfering RNAs (siRNAs), which have shown promise in diminishing the expression of CD320 and LRP2 proteins. Preliminary studies suggest that the dual knockdown of these proteins can be highly cytotoxic to cancer cells while leaving healthy cells unharmed. This novel mechanism presents an opportunity for creating targeted therapies that diverge from conventional biomarker-based treatments.

William Bauta, PhD, Chief Science Officer at BioAffinity Technologies, expressed enthusiasm about the potential of this research to uncover a fundamental vulnerability in cancer cells, which might lead to highly selective and effective therapies. Maria Zannes, President and CEO, underscored the importance of this patent as a significant enhancement to their pipeline, driving forward the company’s mission to deliver effective, noninvasive diagnostic and treatment options for early-stage cancer.

Related news for (BIAF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.